Corneal in vivo confocal microscopy to detect belantamab mafodotin-induced ocular toxicity early and adjust the dose accordingly: a case report

Abstract Background New targeted antibody–drug conjugates (ADCs) against multiple myeloma are known to induce adverse effects that may lead to treatment discontinuation. Preclinical studies reported early severe ocular damage related to the use of belantamab mafodotin (belamaf), including ocular sur...

Full description

Bibliographic Details
Main Authors: Kevin Marquant, Anne Quinquenel, Carl Arndt, Alexandre Denoyer
Format: Article
Language:English
Published: BMC 2021-10-01
Series:Journal of Hematology & Oncology
Subjects:
Online Access:https://doi.org/10.1186/s13045-021-01172-5